Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.3K
3.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

38.1K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: A broadly protective antibody targeting gammaherpesvirus gB.

Nature·2026
Same author

Vitamin B6 Ameliorates Lipopolysaccharide-Induced Inflammation in Mouse Gastric Organoids.

Cell biology international·2026
Same author

Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

ENO2 drives tumor cell-induced M2 macrophage polarization to promote colorectal cancer liver metastasis.

Signal transduction and targeted therapy·2026
Same author

Extracellular Vesicle-Transferred ATP-Citrate Lyase Induces Monocyte Differentiation Toward Tumor-Associated Macrophages and Fuels Hepatocellular Carcinoma Progression.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

EBV strain interacts with host HLA to drive nasopharyngeal carcinoma risk.

Nature·2026

Related Experiment Video

Updated: Dec 25, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.4K

Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming.

Jia Liu1, Ze-Xian Liu1, Qi-Nian Wu1

  • 1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.

Nature Communications
|March 22, 2020
PubMed
Summary

The long noncoding RNA Actin Gamma 1 Pseudogene (AGPG) promotes cancer cell growth by stabilizing the PFKFB3 protein, increasing glycolysis. Inhibiting AGPG shows promise for esophageal cancer therapy.

More Related Videos

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
09:36

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

Published on: April 10, 2018

26.1K

Related Experiment Videos

Last Updated: Dec 25, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.4K
RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
09:36

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

Published on: April 10, 2018

26.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Tumor cells exhibit metabolic reprogramming to support rapid proliferation.
  • The function of long noncoding RNAs (lncRNAs) in cancer metabolism is not fully understood.

Purpose of the Study:

  • To investigate the role of lncRNAs in metabolic reprogramming in esophageal squamous cell carcinoma (ESCC).
  • To elucidate the mechanism by which lncRNAs influence cancer metabolism and proliferation.

Main Methods:

  • Screening of lncRNAs involved in glycolysis and cell proliferation in ESCC.
  • Investigating the interaction between AGPG and PFKFB3 using biochemical assays.
  • Assessing the effect of AGPG inhibition on tumor growth in patient-derived xenograft (PDX) models.

Main Results:

  • The lncRNA Actin Gamma 1 Pseudogene (AGPG) was identified as crucial for enhanced glycolysis and proliferation in ESCC.
  • AGPG binds to and stabilizes PFKFB3 by preventing its proteasomal degradation, leading to increased glycolytic flux.
  • Loss or mutation of TP53 results in the upregulation of AGPG.
  • Inhibition of AGPG significantly reduced tumor growth in PDX models.

Conclusions:

  • AGPG promotes cancer cell proliferation by stabilizing PFKFB3 and enhancing glycolysis.
  • AGPG is a transcriptional target of p53, and its expression is upregulated upon TP53 loss.
  • AGPG is a potential therapeutic target and biomarker for esophageal squamous cell carcinoma and other cancers.